Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP180460.RAdnAePVXhZs4AQXsPtWy9yByf_mXn0liTlHm41ccKCoU130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP180460.RAdnAePVXhZs4AQXsPtWy9yByf_mXn0liTlHm41ccKCoU130_provenance.
• NP294474.RAWQnyDsl--JyA9dr1htBvwhh74SfCT-dPAJOO4r55PJg130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP294474.RAWQnyDsl--JyA9dr1htBvwhh74SfCT-dPAJOO4r55PJg130_provenance.
• assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP349244.RAYYC4pXMQGXV3FQqp0Ijk-ObY2-QKzMdj3UeeUA_ku7M130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP349244.RAYYC4pXMQGXV3FQqp0Ijk-ObY2-QKzMdj3UeeUA_ku7M130_provenance.
• NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_provenance.
• NP851667.RAV99qIHZpnFWryVE-oANAoSGsPR3-sKVIs4P3vG91qgg130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851667.RAV99qIHZpnFWryVE-oANAoSGsPR3-sKVIs4P3vG91qgg130_provenance.
• NP851668.RAdQazKkBg3dKSNsWLAVAiK9i5uvNDBej6E3U4YB0itYg130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851668.RAdQazKkBg3dKSNsWLAVAiK9i5uvNDBej6E3U4YB0itYg130_provenance.
• NP851672.RAdKyiSziNj2RFekKHBuW_T_8kPA8Au8yVvBN6f7LhP0Y130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851672.RAdKyiSziNj2RFekKHBuW_T_8kPA8Au8yVvBN6f7LhP0Y130_provenance.
• NP229191.RAiWFzQC0L5Z6cius2uhtOYv524siQQdVU85BCv13IydQ130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP229191.RAiWFzQC0L5Z6cius2uhtOYv524siQQdVU85BCv13IydQ130_provenance.
• NP348986.RAj2cwdUaXIEt_Q6EIx3rffe9mV6QYLS9QbwBgwp7R8NI130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348986.RAj2cwdUaXIEt_Q6EIx3rffe9mV6QYLS9QbwBgwp7R8NI130_provenance.
• NP851676.RArOPoO_WdECRZx6XxSrBhuEmSln5c_GVS8WFNNuWgZqo130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851676.RArOPoO_WdECRZx6XxSrBhuEmSln5c_GVS8WFNNuWgZqo130_provenance.
• NP229798.RAGOzgZ3af-CVLn6VlU6r1f558yOtwUOXZKKWyGEIATvA130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP229798.RAGOzgZ3af-CVLn6VlU6r1f558yOtwUOXZKKWyGEIATvA130_provenance.
• NP350460.RAJY15ESXZxVlJY-wbFp3l2HJgmwUW9dbxE_ROgRaoqBQ130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350460.RAJY15ESXZxVlJY-wbFp3l2HJgmwUW9dbxE_ROgRaoqBQ130_provenance.
• NP851674.RAL71v0dvgimdo41EI7SfPUjn0MPdGiBYyKNqn97M2d4c130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851674.RAL71v0dvgimdo41EI7SfPUjn0MPdGiBYyKNqn97M2d4c130_provenance.
• NP851675.RA-iwXcIhKXqkLOEQsGAU7hMDLb-am57xNj_dsDeX3iEI130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP851675.RA-iwXcIhKXqkLOEQsGAU7hMDLb-am57xNj_dsDeX3iEI130_provenance.